Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Deals

Eisai and SEED Therapeutics Join Forces on Molecular Glue Degraders for Neurodegeneration and Cancer

Fineline Cube Aug 8, 2024

Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, and SEED Therapeutics Inc., a U.S....

Company Drug

Servier’s Voranigo Receives FDA Nod for IDH Inhibitor as Brain Tumor Treatment

Fineline Cube Aug 8, 2024

The U.S. Food and Drug Administration (FDA) has granted first-time approval for Voranigo (vorasidenib), a...

Company

Organon’s Q2 2024 Revenues Grow 2% YOY, Sets Sights on Fertility Business Rebound in 2025

Fineline Cube Aug 8, 2024

Organon (NYSE: OGN), a U.S.-based pharmaceutical company, has reported its financial results for the second...

Company Drug

Akeso Biopharma Initiates Phase III Clinical Trial for Cadonilimab in Hepatocellular Carcinoma

Fineline Cube Aug 7, 2024

Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has announced the first patient...

Policy / Regulatory

China’s NMPA Proposes New Rules for Export Drug Manufacturing and Management

Fineline Cube Aug 7, 2024

The National Medical Products Administration (NMPA) of China has issued a new set of regulations...

Company Deals

JiAnTeBo and Sanyou Biopharmaceuticals Join Forces to Discover Metabolic Disease Targets and Develop Agonistic Antibodies

Fineline Cube Aug 7, 2024

Guangdong JiAnTeBo Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a strategic partnership...

Company Deals

Sangamo Therapeutics and Genentech Join Forces to Develop Genomic Therapies for Neurodegenerative Diseases

Fineline Cube Aug 7, 2024

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company based in the U.S., has entered...

Company

Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance

Fineline Cube Aug 7, 2024

Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024,...

Company

Zai Lab’s Q2 2024 Revenues Soar 47% YOY, Driven by Vyvgart and Zejula Sales

Fineline Cube Aug 7, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has...

Company Deals

Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia

Fineline Cube Aug 7, 2024

Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese...

Company Deals

CybernaX Secures Licensing Deal with Merck KGaA for Advanced Lipid Storage Technology

Fineline Cube Aug 7, 2024

CybernaX, a biotechnology company based in Nanjing, has entered into a comprehensive licensing agreement with...

Company Deals

Shanghai Vitalgen BioPharma Partners with Novoprotein to Commercialize AaCas12bMax Gene Editor

Fineline Cube Aug 7, 2024

Shanghai Vitalgen BioPharma Co., Ltd, a specialist in cell and gene therapy based in China,...

Company Drug

Walvax Biotechnology’s HPV Vaccine Price Cut Sparks Potential Market Price War in China

Fineline Cube Aug 7, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142) has significantly reduced the price of its bivalent human...

Company Deals

Mabwell Bioscience Partners with Cristália for Biosimilar Denosumab in Brazil

Fineline Cube Aug 7, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has entered...

Company Deals

Daiichi Sankyo and MSD Broaden Partnership to Co-Develop T-Cell Engager MK-6079

Fineline Cube Aug 7, 2024

Daiichi Sankyo (TYO: 4568), a Japanese pharmaceutical company, has announced an expansion of its strategic...

Company

Bayer AG’s Q2 2024 Global Group Sales Rise 3.1%, Driven by Pharmaceuticals and Consumer Healthcare

Fineline Cube Aug 7, 2024

Bayer AG (OTCMKTS: BAYZF), a multinational pharmaceutical and life sciences company headquartered in Germany, has...

Company Drug

Antengene’s Xpovio Receives NDA Approval in Malaysia for Multiple Myeloma Treatment

Fineline Cube Aug 6, 2024

Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced the approval...

Company Medical Device

Israeli Hair Transplant Innovator Hairstetics Launches First Procedure in Asia at Hainan Hospital

Fineline Cube Aug 6, 2024

Hairstetics, an Israeli innovator in the non-absorbable polyamide hair transplant sector, has achieved a milestone...

Company Drug

Hotgen Biotech’s SGC001 Receives NMPA Approval for Clinical Trials in Myocardial Infarction

Fineline Cube Aug 6, 2024

Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...

Company Drug

Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Clinical Trials in Solid Tumors

Fineline Cube Aug 6, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Posts pagination

1 … 344 345 346 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.